4.0 Article

Preclinical Rheumatoid Arthritis: Identification, Evaluation, and Future Directions for Investigation

Journal

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
Volume 36, Issue 2, Pages 213-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2010.02.001

Keywords

Rheumatoid arthritis; Preclinical period; Anticyclic citrullinated peptide antibodies

Categories

Funding

  1. NIAMS NIH HHS [L30 AR050481-02, K23 AR051461-05, K23 AR051461-04, L30 AR050481, K23 AR051461-03, K23 AR051461-01, L30 AR050481-01, K23 AR051461-02, K23 AR051461] Funding Source: Medline

Ask authors/readers for more resources

Rheumatoid arthritis (RA) likely develops in several phases, beginning with genetic risk, followed by asymptomatic autoimmunity, then finally, clinically apparent disease. Investigating the phases of disease that exist prior to the onset of symptoms (ie, the preclinical period of RA) will lead to understanding of the important relationships between genetic and environmental factors that may lead to disease, as well as allow for the development of predictive models for disease, and ultimately preventive strategies for RA.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available